## What CJC-1295 without DAC (Mod GRF 1-29) is
CJC-1295 without DAC (Mod GRF 1-29) is a synthetic 29-amino acid GHRH analog (tetrasubstituted). Mod GRF 1-29 is a tetrasubstituted GHRH analog (Ala2, Gln8, Ala15, Leu27) with ~30-minute half-life (vs ~7 min native GHRH) due to DPP-IV resistance. Lacking DAC's albumin binding, it produces acute pulsatile GH release mimicking physiology, synergizing with GHRPs via complementary cAMP/Ca2+ pathways. It has a molecular formula C152H252N44O42, mass 3367.95 Da. Common synonyms in the literature include Mod GRF 1-29, Modified GRF, and CJC-1295 no DAC. This SKU is a co-formulated blend that also contains Ipamorelin in the same vial — for research groups that want to combine the two under a single reconstitution.
## What it's studied for
Investigation of CJC-1295 without DAC (Mod GRF 1-29) to date is primarily preclinical, with the majority of citations concentrated in animal models and in-vitro assays rather than randomized controlled human trials. Published work referencing CJC-1295 without DAC (Mod GRF 1-29) spans Structure-activity research: Studies established that Ala2 substitution prevents cleavage by dipeptidyl peptidase IV (DPP-IV), the primary GHRH-degrading enzyme. The other substitutions (Gln8, Ala15, Leu27) further enhance stability without compromising receptor binding, Combination research: Preclinical and anecdotal studies suggest GHRH + GHRP combinations produce synergistic GH release. The distinct signaling pathways (cAMP vs. calcium) converge on somatotrophs to amplify secretion beyond additive effects, and Pulsatility preservation: Unlike CJC-1295 DAC, the short half-life of Mod GRF 1-29 allows discrete GH pulses when administered 2-3 times daily. This mimics normal physiological secretion patterns more closely than sustained-release compounds. Proposed mechanisms in the literature include GHRHR full agonism: binds pituitary GHRH receptor, triggering Gs-protein coupling and adenylyl cyclase and cAMP/PKA pathway: adenylyl cyclase → cAMP → PKA activation → GH gene transcription and vesicle release. None of this material describes therapeutic outcomes in humans, and BioInfinity does not sell, market, or provide dosing guidance for CJC-1295 without DAC (Mod GRF 1-29) outside laboratory research.
## Laboratory handling — storage and reconstitution
Lyophilized CJC-1295 without DAC (Mod GRF 1-29) arrives as a fluffy off-white solid inside a sealed sterile vial. Because it ships as a lyophilized research compound (3367.95 Da), the powder is best stored between 2–8 °C prior to reconstitution and returned to −20 °C in aliquots for long-term storage post-reconstitution. Reconstitution is typically performed with bacteriostatic water (0.9 % benzyl alcohol preserved) rather than sterile water because the preservative extends solution stability once the vial has been punctured. Warming the reconstituted solution to room temperature before drawing helps redissolve any peptide that has settled against the vial wall. Avoid repeated freeze–thaw cycles: for peptides in this molecular-weight range (3367.95 Da), freeze–thaw stress is one of the most common causes of loss-of-purity between batches.
## How this batch is verified
Every batch of CJC-1295 without DAC (Mod GRF 1-29) ships with a batch-specific Certificate of Analysis produced by an ISO-accredited third-party analytical laboratory. Reversed-phase HPLC confirms the assay against the expected 3367.95 Da mass (C152H252N44O42); mass spectrometry validates the exact monoisotopic mass; endotoxin (LAL) testing confirms bacterial-contamination limits appropriate for laboratory research; and residual-solvent panels confirm the manufacturing pipeline. The lot number on the outer label matches the COA on the public /coa-library page — every purity claim is independently verifiable before you open the vial.
## Related research
For the full mechanistic profile, published references, and constraint notes on CJC-1295 without DAC (Mod GRF 1-29), see the [CJC-1295 without DAC (Mod GRF 1-29) research page](/research/cjc-1295-no-dac). All references cited on that page are peer-reviewed primary literature.
**Research use only.** CJC-1295 + Ipamorelin is sold strictly for in-vitro and animal research. It is not a drug, food, supplement, or cosmetic and is not intended for human or veterinary consumption. No statements on this page describe or imply any therapeutic effect.
Researchers should refer to peer-reviewed publications for primary sources on this compound. CJC-1295 + Ipamorelin is sold strictly for laboratory research use and is not intended for human or veterinary use.
